News
CYYNF
0.150
NaN%
--
Cynata Updates Proposed Placement and Cymerus Activities
TipRanks · 3d ago
Cynata Proposes Issue of Shares and Options
TipRanks · 11/03 22:57
Cynata Raises $913,000 and Secures Further $550,000 Placement
TipRanks · 11/03 22:57
Cynata Director Increases Holdings Through Entitlement Offer
TipRanks · 11/03 01:48
Cynata Director Takes Up Entitlement Offer Securities
TipRanks · 11/03 01:47
Cynata Applies to Quote 91.3 Million Ordinary Shares
TipRanks · 11/02 23:28
Cynata Completes Share Issue to Support Expanding Stem Cell Pipeline
TipRanks · 10/30 04:58
Cynata Seeks ASX Quotation for 2 Million New Shares
TipRanks · 10/30 04:57
Cynata Engages Director as Consultant to Drive Asset Strategy
TipRanks · 10/30 00:11
Cynata shores up balance sheet with fully underwritten entitlement offer
TipRanks · 10/29 22:54
Cynata Slashes Costs and Raises Capital to Extend Cash Runway to 2028
TipRanks · 10/26 23:19
Cynata moves 2026 AGM to in-person format with digital-first shareholder communications
TipRanks · 10/23 02:17
Cynata’s CYP-001 GvHD Trial Terminated: What Investors Should Know
TipRanks · 10/22 16:30
Cynata Director Paul Wotton to Exit Board as Company Enters New Strategic Phase
TipRanks · 10/22 01:47
Cynata Offers Fee-Free Exit for Small Shareholders via Unmarketable Parcel Facility
TipRanks · 10/19 23:42
Cynata Sets Target Market for New Share Options in Revised Prospectus
TipRanks · 10/12 07:52
Cynata Launches Fully Underwritten Entitlement Offer via Replacement Prospectus
TipRanks · 10/12 06:34
Cynata defines target market for new options in capital raising
TipRanks · 10/07 22:38
Cynata Therapeutics Launches Renounceable Entitlement Offer to Raise Capital
TipRanks · 10/07 22:37
Cynata Plans Issue of 18 Million Options to Support Capital Needs
TipRanks · 10/07 22:37
More
Webull provides a variety of real-time CYYNF stock news. You can receive the latest news about Cynata Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CYYNF
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.